KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AbbVie (ABBV) Common Equity (2016 - 2025)

AbbVie (ABBV) has disclosed Common Equity for 14 consecutive years, with -$3.3 billion as the latest value for Q4 2025.

  • On a quarterly basis, Common Equity fell 198.35% to -$3.3 billion in Q4 2025 year-over-year; TTM through Dec 2025 was -$3.3 billion, a 198.35% decrease, with the full-year FY2025 number at -$3.3 billion, down 198.35% from a year prior.
  • Common Equity was -$3.3 billion for Q4 2025 at AbbVie, down from -$2.6 billion in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $17.3 billion in Q4 2022 to a low of -$3.3 billion in Q4 2025.
  • A 5-year average of $9.4 billion and a median of $12.4 billion in 2021 define the central range for Common Equity.
  • Peak YoY movement for Common Equity: soared 285.21% in 2021, then crashed 198.35% in 2025.
  • AbbVie's Common Equity stood at $15.4 billion in 2021, then grew by 11.99% to $17.3 billion in 2022, then crashed by 39.86% to $10.4 billion in 2023, then plummeted by 68.02% to $3.3 billion in 2024, then plummeted by 198.35% to -$3.3 billion in 2025.
  • Per Business Quant, the three most recent readings for ABBV's Common Equity are -$3.3 billion (Q4 2025), -$2.6 billion (Q3 2025), and -$183.0 million (Q2 2025).